Designer Aspirin Fights Cancer

Early experiments show that a hybrid form of the common pain reliever can effectively inhibit the growth of many tumor types.

By | March 5, 2012

image: Designer Aspirin Fights Cancer Wikimedia Commons, Chaval Brasil


Researchers in New York claim that new type of aspirins can slow the growth of colon, pancreas, breast, lung, and prostate cancers, as well as some types of leukemia. Scientists at the City University of New York Medical School created four new forms of aspirin that release both nitric oxide (NO) and hydrogen sulfide (H2S). They report the anti-cancer properties of these so-called NOSH-Aspirins in a paper published online in ACS Medicinal Chemistry Letters

Though regular aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have shown promise in curtailing tumor growth by knocking back inflammation, they come with nasty side effects such as the risks of gastrointestinal and brain bleeding and liver toxicity. The NOSH-Aspirins tested, on the other hand, did not seem to damage surrounding cells. Plus, one the new aspirins tested appeared to be more than 100,000 times more effective against cancer than normal aspirin.


Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Inside a Lab Mouse’s High-Fat Diet
  2. Battling the Bulge
    Bio Business Battling the Bulge

    Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

  3. How Gastric Bypass Can Kill Sugar Cravings
  4. Birth of the Skin Microbiome
    Daily News Birth of the Skin Microbiome

    The immune system tolerates the colonization of commensal bacteria on the skin with the aid of regulatory T cells during the first few weeks of life, a mouse study shows.

Life Technologies